Spexis Ag Is A Clinical Stage Biopharmaceutical Company Based In Allschwilswitzerlandthe Company Focuses On Developing First In Class Macrocyclic Drugs Aimed At Oncology And Rare Diseaseswith Over 25 Years Of Research And Significant Investments In R&Dspexis Is Dedicated To Addressing High Need Areas Such As Antimicrobial Resistance And Cancer The Company S Pipeline Includes Several Promising Candidatesbalixafortide Is A Cxcr4 Antagonist Currently In Phase Ib Iia Trials For Pancreatic Ductal Adenocarcinoma And Has Been Studied For Advanced Breast Cancerlonodelestat Is A Neutrophil Elastase Inhibitor Ready For Phase 2 Trials Targeting Cystic Fibrosis And Severe Lung Diseasesmurepavadin Is An Inhaled Antibiotic For Cystic Fibrosis Patientsand The Company Also Develops Antibiotics Targeting Gram Negative Bacteria Through Its Ompta Platformspexis Actively Seeks Partnerships And Funding To Advance Its Clinical Programs And Platform Technologies
